VA
KURA icon

VR Adviser’s Kura Oncology KURA Stock Holding History

VR Adviser’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-575,000
Closed -$12M – 31
2021
Q2 		$12M Hold
575,000
– – 1.45% 21
2021
Q1 		$16.3M Hold
575,000
– – 1.76% 17
2020
Q4 		$18.8M Hold
575,000
– – 2.76% 11
2020
Q3 		$17.6M Hold
575,000
– – 3.45% 11
2020
Q2 		$9.37M Buy
+575,000
New +$8.29M 2.24% 11

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

VR Adviser's KURA Position: Q3 2021 in Review

VR Adviser sold out of Kura Oncology (KURA) in Q3 2021, closing a stake of 575,000 shares — an estimated $12M sold.

VR Adviser first reported a position in KURA in Q2 2020 and held it in 5 quarters. The position peaked at $18.8M in Q4 2020. 152 funds tracked by Wall St. Rank hold KURA as of Q3 2021.

  • VR Adviser reported no remaining Kura Oncology position as of Q3 2021 after selling out during the quarter.
  • VR Adviser sold 575,000 Kura Oncology shares in Q3 2021, an estimated $12M.
  • VR Adviser first reported a position in Kura Oncology in Q2 2020 and held it in 5 quarters.
  • VR Adviser's Kura Oncology position peaked at $18.8M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2021.

Based on VR Adviser's 13F filing for Q3 2021, filed 15 Nov 2021.